Kuros Biosciences experienced a 149% increase in direct MagnetOs sales, reaching CHF 50.6 million in the first nine months of 2024.

Kuros Biosciences reported a 149% surge in direct MagnetOs sales, reaching CHF 50.6 million in the first nine months of 2024. Total sales in the Kuros Medical Devices segment rose to CHF 51.1 million in Q3 2024. The company exceeded cash flow breakeven for the first time and achieved a 26% EBITDA margin. Kuros is investing in Project Fusion, with ongoing clinical trials, and has expanded its market presence in the UAE, Qatar, Australia, and the UK.

October 10, 2024
8 Articles

Further Reading